Earnings Call · Q4 FY2022·2022-09-27

Q4 22EPS -32.43%·Rev n/aQ3 22EPS -100.00%*·Rev n/aQ2 22EPS +24.14%·Rev n/aQ1 22EPS -100.00%*·Rev n/a⚠ consensus missing

AYTU BIOPHARMA, INC AYTU

Robert Blum — Investor Relations or Communications

Josh Disbrow — Chief Executive Officer

Mark Oki — Chief Financial Officer

0.0%1d on move date−2.0% vs SPY3d0.0%5d+5.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AYTU calls or request research access.

More AYTU calls Browse calls Request research access